Infectious Disease Diagnostics Market Forecasts to 2028 – Global Analysis By Technique (Traditional, Molecular), End User (Hospitals & Clinics, Diagnostic Reference Laboratories, Academic Research Institutes) and By Geography

Infectious Disease Diagnostics Market Forecasts to 2028 – Global Analysis By Technique (Traditional, Molecular), End User (Hospitals & Clinics, Diagnostic Reference Laboratories, Academic Research Institutes) and By Geography

According to Stratistics MRC, the Global Infectious Disease Diagnostics Market is accounted for $30.69 billion in 2022 and is expected to reach $52.03 billion by 2028 growing at a CAGR of 9.2% during the forecast period. Disease diagnostics are used for confirmation of a disease in form of a quick, precise test result. The infectious disease epidemics are exploding worldwide, raising an extensive demand for diagnostic tests.

In 2020, molecular technologies accounted for approximately 49 percent of the worldwide organ transplant diagnostics market. This was followed by serology which had a 30 percent market share. By 2031, it was forecast that the market share of molecular technologies would increase to just under 54 percent. In 2020, PCR accounted for approximately 42.7 percent of the worldwide molecular diagnostics market, while next-generation sequencing amounted to 10.4 percent of the market. By 2031, PCR was forecast to have a 43.3 percent share of the molecular diagnostics market.

Market Dynamics:

Driver:

Rising prevalence of infectious diseases

The prevalence of infectious diseases in developed and developing regions will positively influence the growth of the infectious disease diagnostics market. The diagnosis and management of such diseases are responsible for the increasing number of prescriptions for infectious disease diagnostic tests. These factors, alongside the growing trend for preventive medicine, are expected to drive the demand for infectious disease diagnostics during the forecast period. The broad-scale population-based testing is required to improve prevention and control efforts for COVID-19. These tests are performed by infectious disease diagnostics. Hence, it is expected to have a positive impact on this market.

Restraint:

Inadequate reimbursement

Inadequate reimbursement is a major factor restraining the growth of the infectious disease diagnostics market. A major challenge that most diagnostic companies face in commercializing their tests is getting health insurers to pay for them.

Opportunity:

Opportunities from developing economies

Developing economies such as India and South Korea are expected to offer potential growth opportunities for major players operating in the infectious disease diagnostics market. This can be attributed to the high disease prevalence, large patient population, improving healthcare infrastructure, increasing disposable income, and growing medical tourism in these countries. In addition to the factors mentioned above, the Asia Pacific has emerged as an adaptive and business-friendly hub due to relatively less stringent regulations and data requirements.

Threat:

Poor distribution channel

Diagnostic kits are expensive and manufacturers still have poor distribution channel for operating across emerging economies. These two factors are projected to be the key challenges to rapid revenue growth of the global infectious diseases diagnostics market.

Covid-19 Impact

Diagnostics for SARS-CoV-2 screening are being developed continuously to cater to the needs of markets with unique regulatory constraints. For example, in November 2021, Detect, a health technology firm, launched a new PCR-quality at-home Covid-19 quick molecular test to address testing needs at home, school, and work, in the United States. Likewise, CoviSwift, by Mylab Discovery Solutions, a point-of-care (POC) RT-PCR testing solution that may be utilized in small labs, in-hospital labs, airports, and communities, was approved and launched in February 2022. Similarly, Abbott introduced the RealTime SARS-CoV-2 assay, a PCR-based test for the diagnosis of COVID-19, in March 2020, and BioMedomics released a PoC COVID-19 test that can identify antibodies in blood within 15 minutes in March 2020.

The reagents, kits, and consumables segment is expected to be the largest during the forecast period

The reagents, kits, and consumables segment is expected to be the largest during the forecast period owing to the factors such as increasing prevalence of infectious diseases, rising awareness among the population to identify the diseases, and increasing use of kits and reagents to identify the organism causing various diseases in lesser time and cost. Further, the outbreak of coronavirus (COVID-19) disease is further expected to accelerate the growth of this segment owing to the national emergency declared and requirement of various kits and assays for early disease detection.

The traditional segment is expected to have the highest CAGR during the forecast period

The dominance of traditional segment is mainly attributed to factors such as the increasing use of immunoassays in infectious disease testing, development of novel tests, rising trend of automation, increasing awareness about health and fitness, and reduced complications associated with the instruments.

Region with largest share:

North America is projected to hold the largest market share owing to the highly developed healthcare system in the US and Canada, the presence of many leading national clinical laboratories, and the easy accessibility to technologically advanced instruments. Other factors contributing to the market growth are the increasing prevalence of infectious diseases and high expenditure on healthcare, and an increase in awareness among the population regarding the availability of treatment devices.

Region with highest CAGR:

Asia Pacific is projected to have the highest CAGR due to the rapid urbanization, increasing investments by healthcare providers towards infrastructure improvement, need to manage growing burden of infectious diseases, and government efforts to improve accessibility of diagnostic services to enhance the prevention by developing products or platforms required for the diagnosis of infectious diseases.

Key players in the market

Some of the key players profiled in the Infectious Disease Diagnostics Market include Becton, Dickinson and Company (BD), Abbott Diagnostic, Beckman Coulter, Siemens Healthcare Diagnostics, Roche Diagnostic, Thermo Fisher Scientific, Bio-Rad Laboratories, Meridian Bioscience, Corgenix, Trinity Biotech, Eiken Chemical, J.Mitra, Diasorin, EMD Millipore, and QuantuMDx.

Key developments:

In July 2021: QuantuMDx launched the rapid polymerase chain reaction point-of-care diagnostic system called Q-POC for COVID-19.

In March 2021: Roche Diagnostics Launched cobas SARS-CoV-2 Variant Set 1 Test to help monitor emerging coronavirus mutations.

In February 2021: Thermo Fisher Scientific acquired Mesa Biotech (US) to expand the benefits of molecular diagnostics at the point of care.

Products Covered:
• Reagents, Kits, and Consumables
• Instruments & Systems
• Software & Services

Test Types Covered:
• Laboratory Tests
• Imaging Test
• Point-of-Care (POC) Testing

Disease Types Covered:
• Bacterial Infection (Methicillin-resistant Staphylococcus Aureus (MRSA))
• Viral Infection
• Hepatitis C
• Hepatitis B
• Cardiovascular Infection
• Fungal Infection
• Hospital Acquired Infections (HAIs)
• Respiratory Infections
• Blood Infections
• Diarrheal Disease
• Central Nervous System (CNS) Infection
• Sexually Transmitted Diseases

Techniques Covered:
• Traditional
• Molecular

End Users Covered
• Hospitals & Clinics
• Diagnostic Reference Laboratories
• Academic Research Institutes
• Home Healthcare
• Physician Offices
• Contract Research Organization
• Surgical Centers

Regions Covered:
• North America
US
Canada
Mexico
• Europe
Germany
UK
Italy
France
Spain
Rest of Europe
• Asia Pacific
Japan
China
India
Australia
New Zealand
South Korea
Rest of Asia Pacific
• South America
Argentina
Brazil
Chile
Rest of South America
• Middle East & Africa
Saudi Arabia
UAE
Qatar
South Africa
Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2020, 2021, 2022, 2025, and 2028
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements